Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2018

Open Access 06.06.2018 | Clinical trial

Machine-learning-derived classifier predicts absence of persistent pain after breast cancer surgery with high accuracy

verfasst von: Jörn Lötsch, Reetta Sipilä, Tiina Tasmuth, Dario Kringel, Ann-Mari Estlander, Tuomo Meretoja, Eija Kalso, Alfred Ultsch

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2018

Abstract

Background

Prevention of persistent pain following breast cancer surgery, via early identification of patients at high risk, is a clinical need. Supervised machine-learning was used to identify parameters that predict persistence of significant pain.

Methods

Over 500 demographic, clinical and psychological parameters were acquired up to 6 months after surgery from 1,000 women (aged 28–75 years) who were treated for breast cancer. Pain was assessed using an 11-point numerical rating scale before surgery and at months 1, 6, 12, 24, and 36. The ratings at months 12, 24, and 36 were used to allocate patents to either “persisting pain” or “non-persisting pain” groups. Unsupervised machine learning was applied to map the parameters to these diagnoses.

Results

A symbolic rule-based classifier tool was created that comprised 21 single or aggregated parameters, including demographic features, psychological and pain-related parameters, forming a questionnaire with “yes/no” items (decision rules). If at least 10 of the 21 rules applied, persisting pain was predicted at a cross-validated accuracy of 86% and a negative predictive value of approximately 95%.

Conclusions

The present machine-learned analysis showed that, even with a large set of parameters acquired from a large cohort, early identification of these patients is only partly successful. This indicates that more parameters are needed for accurate prediction of persisting pain. However, with the current parameters it is possible, with a certainty of almost 95%, to exclude the possibility of persistent pain developing in a woman being treated for breast cancer.
Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s10549-018-4841-8) contains supplementary material, which is available to authorized users.
Eija Kalso and Alfred Ultsch have equally contributed to this work.

Introduction

Breast cancer is the most common cancer in women in the developed countries and its prevalence is steadily increasing [3, 15, 17]. Improved management of breast cancer has made survivorship issues important [41], including moderate to severe pain reported with a prevalence of about 15% at 1 year from surgery [37]. About 34% of these patients have signs of neuropathic pain [48] and the pain can last for several years [36], significantly impairing their quality of life [52]. Prevention of persistent post-surgical pain requires early identification of patients at the highest risk to initiate appropriate medical and psychosocial interventions [10, 43]. On the other hand, identifying patients in whom the possibility of persistent pain can be dismissed with high confidence may be similarly desirable as this could prevent unnecessary therapeutic interventions.
The prediction of persistent pain after a surgical intervention is therefore an active research topic that has already led to several proposed solutions, as indicated by 160 hits in a PubMed search at https://​www.​ncbi.​nlm.​nih.​gov/​pubmed for “(chronic or persistent) and pain and prediction and *surgery” on December 6, 2017. However, diagnostic tools providing such a prediction have remained an unmet clinical need. Considering that pain has a highly complex pathophysiology [22, 47] and is triggered by several different causes including cancer [44] and surgery [25], such tools may require a combination of different parameters. However, in addition to proposals of biochemical or genetic markers, clinical and psychological parameters have remained a basis of predictive assessments of the development of pain after surgery [4, 11, 30, 37].
In the present analysis, more than 500 parameters were available from a 3-year follow-up of 1,000 women operated on for breast cancer [49]. This provided a robust basis for clinical judgment of pain persistence and, using parameters acquired during the perioperative period, allowed the prediction of either persistent pain at later stages or its unlikeliness. Previous analyses indicated the suitability of these parameters for the prediction of persistent pain [32, 49]; however, the present analysis used a data-driven approach, without prior hypotheses on the most important parameters, to create a predictive diagnostic tool for persistent pain, or its absence, following breast cancer surgery and adjuvant therapies.

Methods

Patients

The study followed the Declaration of Helsinki, and both the Coordinating Ethics Committee (journal number 136/E6/2006) and the Ethics Committee of the Department of Surgery (148/E6/05) of the Hospital District of Helsinki and Uusimaa approved the study protocol. Written informed consent for data acquisition and publication in an anonymized manner was obtained from each participating patient. One thousand women with unilateral non-metastasized breast cancer, aged 28–75 years (Fig. 1) were enrolled during the preoperative visit before breast cancer surgery. They were treated at the Helsinki University Hospital between 2006 and 2010 with breast-conserving surgery or mastectomy, and sentinel node biopsy and/or axillary clearance. Exclusion criteria were neoadjuvant therapy, i.e., administration of chemotherapy to shrink the tumor before the main surgical treatment [54], and immediate breast reconstruction surgery. Of the 1,536 consecutive eligible patients, 1,149 patients were invited to participate, of whom 126 patients declined and 23 were withdrawn.
The cohort has previously been described in detail [24, 37]. Briefly, perioperative analgesia was standardized, consisting of oral acetaminophen and intravenous oxycodone, titrated first by a research nurse in the post-anesthesia care unit followed by patient-controlled analgesia on the ward. No regional anesthesia was used. Analgesia at home during the first postoperative week consisted of ibuprofen, acetaminophen or a combination of acetaminophen and codeine. Adjuvant treatments were given according to international guidelines [37].

Data acquisition

Acquisition of data on pain during the follow-up

A full listing of the acquired data is provided in Supplementary Table 1. Pain was assessed using a standard 11-point Numerical Rating Scale (NRS) ranging from 0 to 10, 0 indicating “no pain” and 10 the “worst imaginable pain” [12]. The mean daily post-surgical pain intensity was recorded during the first postoperative week with patient-rated paper diaries. At 1, 6, 12, 24, and 36 months after surgery, questionnaires were posted to all patients asking about the presence, location, and intensity of pain, pain interference, and mood. The patients reported, as a single rating, the worst pain, either at rest or during movement, in any of the surgery-related locations (breast, axilla, upper arm) during the previous week. The questionnaires about pain interference with daily life and sleep were developed for this study. The presence or absence of persistent pain was established from these questions at 12–36 months.

Acquisition of candidate parameters for prediction of pain persistence

To predict the development or absence of persistent pain after breast cancer surgery, the so-called “input space” of 542 different variables was acquired from the data collected before surgery, during the perioperative phase, and at follow-up until 6 months after surgery. The acquired variables, in the present context of machine-learning [39] called parameters or “features,” included the patients’ medical history (diseases, medications, number of previous surgeries), and demographic data. In addition, pain-related data included the presence of persistent pain of any kind, preoperative pain in the operated area (breast, axilla, arm), opioid (remifentanil) consumption during surgery, immediate postoperative pain intensity ratings (at rest and during movement), amount of oxycodone needed for satisfactory pain relief for the first time after surgery, oxycodone consumption during 20 h after surgery, pain intensity, and analgesic consumption during the first postoperative week. The parameters also included surgical data such as type of surgery (mastectomy or breast-conserving surgery, axillary clearance, sentinel node biopsy), complications of surgery and re-operations, pathology data such as tumor and lymph node characteristics. Finally, data on adjuvant therapies (chemotherapy, radiation therapy, endocrine therapy) were acquired.
In the follow-up questionnaires, detailed pain-related parameters about specific pain locations were sought and the patients were asked whether the pain had disturbed their sleep or otherwise affected their life (11-points NRS ranging from 0 to 10, 0 indicating “not at all” and 10 “very much”), and what analgesics they used, if any. Psychological data were acquired with questionnaires including Beck’s Depression Inventory (BDI) [2] and Spielberger’s State-Trait Anxiety Inventory (STAI) [51] before surgery and at the follow-up times. The State-Trait Anger Expression Inventory (STAXI2) [50] was used preoperatively and at 6 months. All data were entered manually into Excel files and double-checked by two investigators.

Data analysis

Data analysis was performed using the MATLAB numerical computing environment (version 8.3.0.532, MathWorks, Natick, MS, USA) and R software package (version 3.2.3 for Linux; http://​CRAN.​R-project.​org/​ [45]).
Application of the previously proposed six-factor risk index for persisting pain was performed according to the instructions in Table A1 in the appendix of [49]. In brief, the six items “age,” “chronic pain of any kind,” “number of previous operations,” “body mass index,” “preoperative pain in the area to be operated on,” and “smoking” were weighted according to these instructions. For example, age ≤ 39 years was given a weight of 0, age 40–69 years a weight of 8, and age ≥ 70 years a weight of 16. The respective weights for the six parameters were added from an index of 20, patients were predicted as potentially developing persisting pain.
Given the broader data basis available in the present analysis, a novel and independently designed analysis was performed to assess whether the classification performance could be improved. This was approached using supervised machine-learning [39] and feature-selection techniques [19], aimed at identifying parameters from the data acquired before surgery and up to the sixth month after surgery, which could predict the presence or absence of persisting pain in the area operated on during the 3-year follow-up available for the present analysis. However, as before [49] an interpretable and clinically immediately applicable diagnostic tool was desired and therefore, a rule-based classifier [59] was again chosen forming a questionnaire with “yes/no” items (decision rules). The analysis was performed in four main steps as shown in Fig. 2 and comprising (i) establishment of the so-called output space, (i) feature pre-selection, (iii) feature selection, and (iv) classifier building, which are described briefly in the following; more detailed descriptions are provided in the Supplementary materials.
First, the so-called “output space” was established (Fig. 2 left part) by identifying the groups or “classes” of patients with respect to persistent pain. In the following, the term “persisting pain group” and “non-persisting pain group” or “classes” will be used when referring to these groups. Subsequently, the input or feature space was analyzed to identify those parameters that provided a valid assignment of a patient to the classes of persisting or non-persisting pain. This included the second analytical (Fig. 2 right part) step comprising a “feature” pre-selection, during which all parameters were analyzed with respect to differences between the “persisting pain” and “non-persisting pain” groups, established in the output space. This was based on the assessment of effect sizes between the two patient groups depending on the numerical scaling of the parameters as continuous (interval-scaled), discrete or binary (“yes”/”no”).
Those parameters that had passed that step were taken into the third analytical step of feature selection (Fig. 2 right part), which eliminated all parameters distinguishing between the persisting pain and non-persisting pain groups but not providing additional relevant information justifying their inclusion in a tool (“classifier”) predictive of persisting pain. This applied a so-called calculated ABC analysis [56]. This is an inventory categorization technique originally developed for problems in economics to search for a subset with the minimum possible effort that gives the maximum yield [23, 42]. The remaining parameters, in the following called “features,” were taken into the fourth step of the data analysis (Fig. 2 bottom right) in which the predictive tool or “classifier” was constructed and assessed with respect to standard test performance measures. To obtain a robust selection of parameters (features), Monte-Carlo resampling was used repeatedly.

Results

Persisting versus non-persisting pain groups

The recovery rate of the pain questionnaires was high with 95.3, 91.3, 90.2, 90.2, and 87.4% returned in months 1, 6, 12, 24, and 36, respectively. This sufficed for a valid classification of the subjects into two main diagnostic groups that displayed temporal courses of pain for 3 years after breast cancer surgery obtained in the first analytical step aimed at establishing the so-called output step (Fig. 2 left). Of the 1000 analyzed women (Fig. 1), 779 had a favorable time course of postoperative pain and belonged to the “non-persisting pain” group characterized by NRSmonth12...month36 ≤ 3 (Fig. 1 left). By contrast, in 74 women, the pain followed the opposite path typical for the “persisting pain” group characterized by NRSmonth36 ≥ 4 and NRSmonth12...month36 > 0 and (NRSmonth36 − NRSmonth24) ≥ 0 (Fig. 1 middle). Four of these women were excluded from the analysis due to breast reconstruction surgery within the previous month, which hampered the clear association of pain at month 36 to the original surgery. Finally, the criteria for class assignment were not completely met in the remaining 143 women who were therefore excluded from machine-learned classifier establishment (Fig. 1 right) but were used as an exploratory “test” data set.

Classifier establishment

Supervised machine-learning was applied to map the “input space,” i.e., the acquired “features” (the 542 parameters), x, to the “classes,” i.e., the outputs, y, given the data subset of the input–output pairs \(D=\left\{ {\left( {{x_i},{y_i}} \right)|{x_i} \in X,~{y_i} \in Y,~i=1 \ldots n} \right\}\) that comprised the n = 849 patients belonging to the two groups (persisting or non-persisting pain). Feature pre-selection (data analysis step 2; Fig. 2 right part) identified 39 parameters for which the analysis of probability of belonging to the “persisting pain” group, i.e., \(p\left( {y={y_1}|x,D} \right)\), was in principle possible. During feature selection (data analysis step 3; Fig. 2 right part), among these 39 candidates, ABC analysis picked 21 parameters (features) six continuous and 15 discrete variables (Fig. 2) that provided a substantial contribution to the sensitivity and specificity of a classifier for a patient’s assignment to one of the groups (persisting pain or non-persisting pain). The process of feature selection via 1,000 resampling and ABC analyses is shown in Fig. 3 for the 17 continuous variables, of which only six passed the analytical step due to their consistent placement in set “A” comprising the parameters most suitable as predictors.
A rule-based classifier [59] was obtained during analytical step 4 (Fig. 2 bottom right). It took the shape of a diagnostic tool shown in Table 2 consisting of a set of items presented as “yes” or “no” decisions. The diagnostic tool comprised three main categories of variables, i.e., demographic, psychological, and pain-related parameters (features). For each item, the prediction of persistent pain, i.e., the assignment of a patient to the “persisting pain” group (output space), was likely at a specific threshold shown in the right column of Table 2. The number of positive decisions by which a patient was classified into the “persisting pain” group was established testing all possible feature combinations. This analysis resulted in a threshold of 9.5 (Fig. 4), which indicates that when at least 10 of the 21 rules listed in Table 2 applied the patient was identified as likely to develop persistent pain. The detailed use of the diagnostic tool is described step-by-step in Textbox 1.
Table 1
Parameter list including original features along with the details of feature aggregation
Number
Parameters (features)
Time
Body location
Preoperative
Week 1
Week 4
Week 24
Breast
Axilla
Upper arm
Joints
Lower arm
Hand/fingers
Operated side arm
Somewhere
1
Age
X
           
2
BMI
X
           
3
Depressive symptoms (BDI)
   
X
        
4
State anxiety (STAI)
   
X
        
5
Trait anxiety (STAI)
   
X
        
6
Anger inhibition (STAXI-2)
X
           
7
Have the pains in the extremities* affected your life?
  
X
  
X
X
X
X
X
  
8
Have the pains in the axilla affected your life?
 
X
X
X
 
X
      
9
Have the pains in the hand or fingers affected your life?
 
X
X
X
     
X
  
10
Have the pains in the joints affected your life?
 
X
X
X
   
X
    
11
Have the pains in the lower arm affected your life?
 
X
X
X
    
X
   
12
Have the pains in the upper arm affected your life?
 
X
X
X
  
X
     
13
How much has the pain disturbed your sleep?
  
X
         
14
How much has the pain disturbed your sleep?
   
X
        
15
How much has the pain in the axilla disturbed your sleep?
  
X
X
 
X
      
16
How much has the pain in the breast disturbed your sleep?
  
X
X
X
       
17
Pain intensity in the operated-side arm and axilla in the morning?
 
X
X
  
X
    
X
 
18
Worst pain intensity during the past week at one month
  
X
 
X
X
X
X
X
X
  
19
Worst pain intensity during the past week at 6 months
   
X
X
X
X
X
X
X
  
20
Worst pain intensity during the past week in the operated breast?
  
X
X
X
       
21
Worst pain intensity during the past week somewhere?
  
X
X
       
X
The table specifies the time points and, if applicable, the targeted body locations for several questions the patients are asked following surgery. Specifically, for the pain-related parameters #7 - #21 (according to the numbering in the left column), patients were asked about how the pain affected their lives or sleep. These questions were asked at several times (week 1, 4, and 24 after surgery) and for several specific body locations (breast, axilla, upper arm, joints, lower arm, hand, arm on operation side, elsewhere) indicated in the middle block of the table. The “X”s indicate which ratings were averaged to obtain the parameters
*Extremities: aggregated parameters across axilla, upper arm, lower arm, hand/fingers, and the associated joints
Table 2
Parameters (predictive factors) for persisting pain following breast cancer surgery
Number
Category
Parameters (predictive factors)
Threshold
1
Demographic factors
Age
> 62
2
BMI
> 31.5
3
Psychological factors
Depressive symptoms (BDI)
> 11
4
State anxiety (STAI)
> 35
5
Trait anxiety (STAI)
> 37
6
Anger inhibition (STAXI)
> 12
7
Pain-related factors
Have the pains in the extremities *affected your life?
> 1.5
8
Have the pains in the axilla affected your life?
> 0.5
9
Have the pains in the hand or fingers affected your life?
> 0.5
10
Have the pains in the joints affected your life?
> 0.5
11
Have the pains in the lower arm affected your life?
> 0.5
12
Have the pains in the upper arm affected your life?
> 0.5
13
How much has the pain disturbed your sleep?
> 0.5
14
How much has the pain disturbed your sleep?
> 0.5
15
How much has the pain in the axilla disturbed your sleep?
> 0.5
16
How much has the pain in the breast disturbed your sleep?
> 0.5
17
Pain intensity in the operated-side arm and axilla in the morning?
> 2.5
18
Worst pain intensity during the past week at one month
> 1.5
19
Worst pain intensity during the past week at 6 months
> 0.5
20
Worst pain intensity during the past week in the operated breast?
> 1.5
21
Worst pain intensity during the past week somewhere?
> 1.5
All
 
“Persistent pain” class if sum of positively answered items ≥ 10
A patient is likely to develop persistent pain if at least 10 of the 21 items (rules) apply
BMI body mass index, BDI Beck’s Depression Inventory, STAI Spielberger’s State-Trait Anxiety Inventory, STAXI Spielberger’s State-Trait Anger Expression Inventory, m months

Textbox 1: Summary of the data acquisition and calculation steps required to apply the diagnostic tool, as presented in Table 2, to a single patient. See Table 1 for details about the items that need to be averaged

  • Observation period for application of the predictive tool defined in Table 2 is 6 months after breast cancer surgery.
  • Query of demographic factors (age, BMI; items 1 and 2 in Table 1).
  • Query of complex psychological questionnaires (STAXI, preoperative), BDI, STAI state, and STAI trait at week 24 postoperative (items 3–6 in Table 1).
  • Query of pain-related ratings addressing how much the pain has affected the patient’s life or sleep during the last week, or querying the pain intensity, globally and also separately for various different body locations (items 7–21 in Table 1).
    • How much pain has affected the patient’s life is queried using an 11-point NRS ranging from 0, not at all, to 10, very much (items 7–12 in Table 1). Items are queried at week 1, 4, and 24 at various body locations and averaged for week 4 across all body locations and for each of six body locations (breast, axilla, upper arm, joints, lower arm, hand/fingers) averaged across weeks 1, 4 and 24.
    • How much pain has affected the patients sleep is queried using an 11-point NRS ranging from 0, not at all, to 10, very much (items 13–16 in Table 1). Items are queried at week 4 and 24, globally (items 13 and 14 in Table 1), or asked specifically for the effect of pain at body locations breast or axilla. Items are queried at week 4 and 24 for the two body locations are averaged per body location (items 15 and 16 in Table 1).
    • Pain intensity in the operated-side arm and axilla (NRS from 0, no pain, to 10, worst imaginable pain), in the morning is queried at week 4 and 24 and averaged across the time points (item 17 in Table 1)
    • The worst pain intensity experienced during the past week (items 18–21 in Table 1) is queried for six body locations (breast, axilla, upper arm, joints, lower arm, hand/fingers) and in addition, for any part of the body (“somewhere”) using an 11-point NRS ranging from 0, not at all, to 10, very much. Items are queried at week 4 and 24 averaged per week across all body locations (items 18 and 19 in Table 1). Ratings for pain in the operated breast or “somewhere” are averaged across weeks 4 and 24 (items 20 and 21 in Table 1)
  • Each of the 21 items (Table 1) obtained as described above is assessed with respect to the Bayesian threshold (Table 2, right column) and the sum of the “yes”/”no” answers to the question: “Above threshold?” are added.
  • Persistent pain is likely when the above sum equals 10 or higher.

Classifier performance

At the end of analytical step 4, the performance of the obtained classifiers to correctly assign a patient to the persisting pain groups was tested and compared with that of the previously proposed six-factor risk index for persisting pain [49] comprising the weighted items “age,” “chronic pain of any kind,” “number of previous operations,” “body mass index,” “preoperative pain in the area to be operated,” and “smoking,” This provided a performance of 70.6% sensitivity and 45.4% specificity for correct assignment of a patient to the persisting pain group. The accuracy for correct group prediction was 47.4%, and the balanced accuracy, which takes unequal group sizes into account, was 57.9%. However, the negative predictive value, which quantifies the probability that persisting pain will not develop when the test is negative, was high with 94.5% correctly excluding a development toward persistent pain.
The novel, more complex, diagnostic tool provided, via 1000 Monte-Carlo random resamplings [18] of 50% of the original data set, a cross-validated classifier performance of 79.3 ± 1.5% sensitivity and 51.4 ± 6% specificity for correct assignment of a patient to the persisting pain group. The overall classification accuracy obtained in the 1,000 runs with resampled data was 86.2 ± 1.4%, and the balanced accuracy was 65.4%. The negative predictive value was again high with 94.8% (binomial confidence interval: 93.4–95.9%).
Finally, the classifier performances were assessed on the 143 patients who did not completely meet the strict criteria of persistent pain but nevertheless displayed an unsatisfactory course of pain development and were therefore used as an exploratory “test” data set. Thus, when only the first criterion of the NRS-based classification into persisting and non-persisting pain groups was applied, i.e., patients with NRS ≤ 3 at month 36 after surgery (NRSmonth36 ≤ 3) were identified as belonging to the “non-persisting pain” group, while those with (NRSmonth36 ≥ 4) had “persisting pain,” 143 patients could be classified. Of these, 21 patients had at 3 years a pain score of ≥ 4 and were therefore considered as having an unfavorable clinical outcome. These patients were thus defined as “presumably having persisting pain” and therefore belonging to the “persisting pain” group. Taking the aforementioned unfavorable outcome as a sign of persisting pain, the 6-item classifier provided sensitivity and specificity of identifying potentially persisting pain of 94.1 and 43.7%, respectively, and an accuracy or balanced accuracy of class assignment of 46.6 or 66.9%, respectively. The more complex novel classifier provided 14 true positive, 3 false negative, 56 false positive, and 70 true negative diagnoses of persistent pain. This translates into sensitivity and specificity of identifying a patient at risk of 82.4 and 55.6%, respectively. The accuracy was 58.7%, the balanced accuracy was 69%, and a negative predictive value of 95.9% was obtained (binomial confidence interval: 88.5–99.1%).

Discussion

The main result from the present machine-learned analysis was that a more complex diagnostic tool than previously proposed for a subgroup of 489 of the present patients [49] improved the correct assignment of a patient to either the persistent or non-persistent pain group, raising accuracy to 86% and balanced accuracy to 65.4%, while maintaining the already high negative predictive value for persistent pain of 95%.
The present criteria of persistent pain differed from the proposal of the International Association for the Study of Pain in two aspects, i.e., (i) the time window was longer, six months instead of two, due to the particular clinical setting of breast cancer surgery, and (ii) the presence of relevant preoperative pain jeopardizing the attribution of postoperative pain to the surgery. Eleven patients of the “persisting pain” group had an NRS value > 3 for preoperative pain. In nine of the 74 patients assigned to the “persisting pain” group (12%), pain at 36 months was less although still > 3/10 NRS. Thus, the definitive criteria for postsurgery pain were not met in these patients and the predictor correctly addressed persistent pain in a breast cancer setting without unequivocally implying a surgical procedure as a causal factor. This should be considered when interpreting and applying the present diagnostic tool.
While in the original 6-item index “age,” “chronic pain of any kind,” “number of previous operations,” “body mass index,” “preoperative pain in the area to be operated,” and “smoking” were included, the novel selected features differed partly from this earlier selection. This probably owes to the longer observation period of the present analysis, and to the different techniques of feature selection. Nevertheless, some parameters agreed including a first major category of predictive features comprised demographic parameters. An increasing prevalence of chronic pain with age has been shown in several epidemiological studies [14]. The prevalence of neuropathic pain is also significantly higher in the elderly [53]. Interestingly, many previous, mainly cross-sectional studies, have reported that younger age would increase the risk for persistent pain after breast cancer treatment [1]. Previous studies have usually included mild pain intensities, whereas we used at least moderate pain as a cut-off. Younger women may report more discomfort related to milder pain due to a more active life style. Similarly, high body weight and chronic pain have been suggested to represent significant comorbidities, adversely impacting each other [40]. The association is not specific to a particular kind of pain but has been seen across several different aetiologies and clinical conditions [8, 20, 38, 40, 46, 60]. Possible physiological moderators include low-grade systemic inflammation and metabolic disorders [7, 29].
The second major category of predictive features emphasized the importance of psychological factors for the persistence of pain. This is in line with evidence that psychological factors play an important role in pain persistence [4, 5, 11, 16, 27, 30, 31, 33, 34, 37]. Psychological factors and pain have bidirectional influences, i.e., psychological factors influence how the patient perceives and interprets pain and vice versa, constant pain may affect psychological factors and have an impact on mood either directly or via its negative effects on sleep, functionality, social, and other activities [57, 58]. Thus, psychological factors may be at the same time predictors, maintainers, changeable variables and consequences of persistent pain [13]. Therefore, psychological factors have been proposed as early predictive markers for the development of persisting pain (e.g., [37]).
In the present study, women at risk of developing persistent pain reported more symptoms of depression and state and trait anxiety. A higher tendency to inhibit anger, as assessed before surgery, was related to pain persistence. Anger inhibition has been suggested to be closely related to general negative affect and depressive symptoms [6], and thus to associate with chronic pain [21]. Similar associations of chronic pain with psychological factors have been reported in several clinical settings not restricted to cancer surgery [5, 16, 27, 31, 33, 34]. Feelings of anxiety and lowered mood preoperatively are natural reactions to a serious disease, especially immediately after diagnosis. Interestingly, the level of psychological wellbeing at 6 months predicted persistent pain at 3 years, suggesting that better psychological coping after the acute phase might associate with lower risk of pain persistence. It might therefore be important to include routine assessment of psychological coping at this time point and initiate appropriate interventions as needed.
Finally, the third major category of predictive features was related to pain. These features were present early on and continued to persist for up to 3 years. Indeed, this is a recognized observation and, due to this, early treatment of pain has become a clinical routine. Interestingly, the early perception that pain impacted the patient’s life did not closely correlate with pain intensity. This was indicated by the lack of significant correlation between the ratings of the magnitude of the impact on the life and the associated NRS ratings of the pain intensity at the first month after surgery (Kendall’s τ = 0.136) [26, 55].

Conclusions

Using a data-driven approach in a cohort of 1,000 women operated on for breast cancer, a set of demographic, psychological, and pain-related parameters available not later than at 6 months after surgery was associated with the persistence of pain in a 3-year follow-up. Applying machine-learning techniques, a classifier was developed that finally took the shape of a questionnaire with “yes/no” decisions about clinical features. Its main clinical strength lies in the exclusion of the possibility of developing persistent pain in a woman being treated for breast cancer with an accuracy of 95% (negative predictive value). This provides a clinically reliable basis to release a patient early from multidisciplinary therapy approaches [9]. However, with not more than 80% sensitivity and roughly 70% specificity, the performance of the novel classifier in predicting chronic pain in a patient remained only moderate. This suggests that the demographic, psychological, and clinical parameters included in the present classifier are insufficient as predictors of persistent pain. Future improvements should be searched for in “omics,” i.e., features based on proteomics, lipidomics, or genomics, to achieve the clinically desired early identification of patients who will develop persistent pain following surgery for breast cancer.

Acknowledgements

The authors thank Les Hearn for proofreading the manuscript.

Compliance with ethical standards

Conflict of interest

The authors have declared no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Gynäkologie

Kombi-Abonnement

Mit e.Med Gynäkologie erhalten Sie Zugang zu CME-Fortbildungen der beiden Fachgebiete, den Premium-Inhalten der Fachzeitschriften, inklusive einer gedruckten gynäkologischen oder urologischen Zeitschrift Ihrer Wahl.

Anhänge

Electronic supplementary material

Below is the link to the electronic supplementary material.
Literatur
2.
Zurück zum Zitat Beck AT, Ward CM, Mendelson M, Mock JE, Erbaugh JK (1961) An inventory for measuring depression. Arch Gen Psychiat 4:561–571CrossRefPubMed Beck AT, Ward CM, Mendelson M, Mock JE, Erbaugh JK (1961) An inventory for measuring depression. Arch Gen Psychiat 4:561–571CrossRefPubMed
8.
9.
Zurück zum Zitat Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, Carter T, Cassidy CL, Chittenden EH, Degenhardt E, Griffith S, Manworren R, McCarberg B, Montgomery R, Murphy J, Perkal MF, Suresh S, Sluka K, Strassels S, Thirlby R, Viscusi E, Walco GA, Warner L, Weisman SJ, Wu CL (2016) Management of postoperative pain: a clinical practice guideline from the american pain society, the american society of regional anesthesia and pain medicine, and the american society of anesthesiologists’ committee on regional anesthesia, executive committee, and administrative council. J Pain 17:131–157. https://doi.org/10.1016/j.jpain.2015.12.008 CrossRefPubMed Chou R, Gordon DB, de Leon-Casasola OA, Rosenberg JM, Bickler S, Brennan T, Carter T, Cassidy CL, Chittenden EH, Degenhardt E, Griffith S, Manworren R, McCarberg B, Montgomery R, Murphy J, Perkal MF, Suresh S, Sluka K, Strassels S, Thirlby R, Viscusi E, Walco GA, Warner L, Weisman SJ, Wu CL (2016) Management of postoperative pain: a clinical practice guideline from the american pain society, the american society of regional anesthesia and pain medicine, and the american society of anesthesiologists’ committee on regional anesthesia, executive committee, and administrative council. J Pain 17:131–157. https://​doi.​org/​10.​1016/​j.​jpain.​2015.​12.​008 CrossRefPubMed
12.
Zurück zum Zitat Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J, IMMPACT (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113:9–19. https://doi.org/10.1016/j.pain.2004.09.012 CrossRefPubMed Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, Kerns RD, Stucki G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad AR, Kramer LD, Manning DC, Martin S, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robbins W, Robinson JP, Rothman M, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Wernicke J, Witter J, IMMPACT (2005) Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain 113:9–19. https://​doi.​org/​10.​1016/​j.​pain.​2004.​09.​012 CrossRefPubMed
15.
17.
Zurück zum Zitat Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabe E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castaneda-Orjuela C, Catala-Lopez F, Chiang P, Chibueze C, Chitheer A, Choi JY, Cowie B, Damtew S, das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer F, TT GH, Gebru A, Gopalani S, Hailu A et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3:524–548. https://doi.org/10.1001/jamaoncol.2016.5688 CrossRefPubMed Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabe E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castaneda-Orjuela C, Catala-Lopez F, Chiang P, Chibueze C, Chitheer A, Choi JY, Cowie B, Damtew S, das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer F, TT GH, Gebru A, Gopalani S, Hailu A et al (2017) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol 3:524–548. https://​doi.​org/​10.​1001/​jamaoncol.​2016.​5688 CrossRefPubMed
18.
Zurück zum Zitat Good PI (2006) Resampling methods: a practical guide to data analysis. Birkhäuser, Boston Good PI (2006) Resampling methods: a practical guide to data analysis. Birkhäuser, Boston
19.
Zurück zum Zitat Guyon I, Andr E (2003) An introduction to variable and feature selection. J Mach Learn Res 3:1157–1182 Guyon I, Andr E (2003) An introduction to variable and feature selection. J Mach Learn Res 3:1157–1182
21.
23.
Zurück zum Zitat Juran JM (1975) The non-Pareto principle; Mea culpa. Qual Prog 8:8–9 Juran JM (1975) The non-Pareto principle; Mea culpa. Qual Prog 8:8–9
32.
Zurück zum Zitat Lötsch J, Ultsch A, Kalso E (2017) Prediction of persistent post-surgery pain by preoperative cold pain sensitivity: Biomarker development with machine-learning-derived analysis. Br J Anaesth aex236 Lötsch J, Ultsch A, Kalso E (2017) Prediction of persistent post-surgery pain by preoperative cold pain sensitivity: Biomarker development with machine-learning-derived analysis. Br J Anaesth aex236
33.
34.
Zurück zum Zitat McCracken LM, Gross RT, Aikens J, Carnrike CL Jr (1996) The assessment of anxiety and fear in persons with chronic pain: a comparison of instruments. Behav Res Ther 34:927–933CrossRefPubMed McCracken LM, Gross RT, Aikens J, Carnrike CL Jr (1996) The assessment of anxiety and fear in persons with chronic pain: a comparison of instruments. Behav Res Ther 34:927–933CrossRefPubMed
35.
Zurück zum Zitat McGrayne SB (2011) The Theory That Would Not Die: How Bayes’ Rule Cracked the Enigma Code, Hunted Down Russian Submarines & Emerged Triumphant from Two Centuries of Controversy. Yale University Press, New Haven McGrayne SB (2011) The Theory That Would Not Die: How Bayes’ Rule Cracked the Enigma Code, Hunted Down Russian Submarines & Emerged Triumphant from Two Centuries of Controversy. Yale University Press, New Haven
39.
Zurück zum Zitat Murphy KP (2012) Machine Learning: A Probabilistic Perspective. The MIT Press, Cambridge Murphy KP (2012) Machine Learning: A Probabilistic Perspective. The MIT Press, Cambridge
41.
Zurück zum Zitat Paice JA, Portenoy R, Lacchetti C, Campbell T, Cheville A, Citron M, Constine LS, Cooper A, Glare P, Keefe F, Koyyalagunta L, Levy M, Miaskowski C, Otis-Green S, Sloan P, Bruera E (2016) Management of chronic pain in survivors of adult cancers: american society of clinical oncology clinical practice guideline. J Clin Oncol 34:3325–3345. https://doi.org/10.1200/jco.2016.68.5206 CrossRefPubMed Paice JA, Portenoy R, Lacchetti C, Campbell T, Cheville A, Citron M, Constine LS, Cooper A, Glare P, Keefe F, Koyyalagunta L, Levy M, Miaskowski C, Otis-Green S, Sloan P, Bruera E (2016) Management of chronic pain in survivors of adult cancers: american society of clinical oncology clinical practice guideline. J Clin Oncol 34:3325–3345. https://​doi.​org/​10.​1200/​jco.​2016.​68.​5206 CrossRefPubMed
42.
Zurück zum Zitat Pareto V (1909) Manuale di economia politica, Milan: Società editrice libraria, revised and translated into French as Manuel d’économie politique. In:Giard et Briére, Paris Pareto V (1909) Manuale di economia politica, Milan: Società editrice libraria, revised and translated into French as Manuel d’économie politique. In:Giard et Briére, Paris
44.
45.
Zurück zum Zitat R Development Core Team (2008) R: a language and environment for statistical computing R Development Core Team (2008) R: a language and environment for statistical computing
47.
Zurück zum Zitat Schaible HG (2007) Peripheral and central mechanisms of pain generation. Handb Exp Pharmacol:3–28 Schaible HG (2007) Peripheral and central mechanisms of pain generation. Handb Exp Pharmacol:3–28
50.
Zurück zum Zitat Spielberger CD (1999) Staxi-2: state-trait anger expression inventory-2; professional manual. PAR, Psychological Assessment Resources Spielberger CD (1999) Staxi-2: state-trait anger expression inventory-2; professional manual. PAR, Psychological Assessment Resources
51.
Zurück zum Zitat Spielberger CD, Gorsuch RL, Lushene RE (1970) The State-Trait Anxiety Inventory (test manual). Consulting Psychologists Press, Palo Alto, California Spielberger CD, Gorsuch RL, Lushene RE (1970) The State-Trait Anxiety Inventory (test manual). Consulting Psychologists Press, Palo Alto, California
52.
Zurück zum Zitat Tasmuth T, von Smitten K, Kalso E (1996) Pain and other symptoms during the first year after radical and conservative surgery for breast cancer. Br J Cancer 74:2024–2031CrossRefPubMedPubMedCentral Tasmuth T, von Smitten K, Kalso E (1996) Pain and other symptoms during the first year after radical and conservative surgery for breast cancer. Br J Cancer 74:2024–2031CrossRefPubMedPubMedCentral
54.
Zurück zum Zitat Trimble EL, Ungerleider RS, Abrams JA, Kaplan RS, Feigal EG, Smith MA, Carter CL, Friedman MA (1993) Neoadjuvant therapy in cancer treatment. Cancer 72:3515–3524CrossRefPubMed Trimble EL, Ungerleider RS, Abrams JA, Kaplan RS, Feigal EG, Smith MA, Carter CL, Friedman MA (1993) Neoadjuvant therapy in cancer treatment. Cancer 72:3515–3524CrossRefPubMed
55.
Zurück zum Zitat Udovičić M, Baždarić K, Bilić-Zulle L, Petrovečki M (2007) What we need to know when calculating the coefficient of correlation? Biochem Med 17:10–15CrossRef Udovičić M, Baždarić K, Bilić-Zulle L, Petrovečki M (2007) What we need to know when calculating the coefficient of correlation? Biochem Med 17:10–15CrossRef
59.
Zurück zum Zitat Weiss SM, Indurkhya N (1995) Rule-based machine learning methods for functional prediction. J Artif Int Res 3:383–403 Weiss SM, Indurkhya N (1995) Rule-based machine learning methods for functional prediction. J Artif Int Res 3:383–403
Metadaten
Titel
Machine-learning-derived classifier predicts absence of persistent pain after breast cancer surgery with high accuracy
verfasst von
Jörn Lötsch
Reetta Sipilä
Tiina Tasmuth
Dario Kringel
Ann-Mari Estlander
Tuomo Meretoja
Eija Kalso
Alfred Ultsch
Publikationsdatum
06.06.2018
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2018
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4841-8

Weitere Artikel der Ausgabe 2/2018

Breast Cancer Research and Treatment 2/2018 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.